Liminal BioSciences

$4.18
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.21 (-4.78%) As of 10:43 AM EST today

Why Robinhood?

You can buy or sell LMNL and other stocks, options, and ETFs commission-free!

About LMNL

Liminal BioSciences Inc. Common Shares, also called Liminal BioSciences, is a biopharmaceutical corporation. The firm engages in the development of therapeutic products focusing on unmet medical needs in the field of fibrosis, autoimmune disease or inflammation and cancer. It operates through the following segments: Small Molecule Therapeutics and Plasma-derived Therapeutics. The Small Molecule Therapeutics segment focuses on discovering, developing and commercializing novel treatments for patients suffering from diseases related to fibrosis, including conditions of the lung, liver and kidney. The Plasma-derived Therapeutics segment provides efficient extraction and purification of therapeutic proteins from human plasma. The company was founded on October 14, 1994 and is headquartered in Laval, Canada. The listed name for LMNL is Liminal BioSciences Inc. Common Shares.

CEO
Bruce Philip Pritchard
Employees
300
Headquarters
Laval, Québec
Founded
1994
Market Cap
98.61M
Price-Earnings Ratio
Dividend Yield
Average Volume
2.16M
High Today
$4.36
Low Today
$4.06
Open Price
$4.36
Volume
358.38K
52 Week High
$31.45
52 Week Low
$3.51

Collections

LMNL Earnings

-$0.74
-$0.49
-$0.25
$0.00
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Estimated
per share
Actual
-$0.74 per share

You May Also Like